Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenylyl Cyclase Type 1 (AC1) is an enzyme that catalyzes the conversion of ATP to cAMP, a key second messenger in cellular signaling pathways. It is specifically activated by calcium ions through calmodulin binding, making it a calmodulin-sensitive adenylyl cyclase. AC1 plays critical roles in the central nervous system, including regulation of neural circuit patterning, involvement in memory acquisition and learning, and modulation of circadian rhythm-related functions. Disruption of AC1 leads to defects in neural pattern formation. Pharmacologically targeting AC1 has shown promise as a novel analgesic strategy.
AC1 catalyzes the conversion of ATP to cAMP, a second messenger involved in various cellular processes. Targeting AC1 can modulate cAMP levels and downstream signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenylyl Cyclase Type 1 (AC1).